{"id":"W3213641350","doi":"10.1182/blood-2021-154195","title":"Venetoclax, Obinutuzumab and Atezolizumab (PD-L1 Checkpoint Inhibitor) for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL)","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Venetoclax; Atezolizumab; Obinutuzumab; Chronic lymphocytic leukemia; Medicine; Ibrutinib; Rituximab; Internal medicine; Oncology; Bendamustine; Alemtuzumab; Leukemia; Pembrolizumab; Cancer; Immunotherapy; Lymphoma; Transplantation","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001497391,0.0004563688,0.0007452004,0.0001190126,0.0002476365,0.00007619825,0.0001354782,0.0002307341,0.00005454994],"category_scores_gemma":[0.0002628686,0.0003575634,0.0002369302,0.0002688292,0.0001619123,0.0001036347,0.0001254638,0.000120038,0.00001917381],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.1559443,"about_ca_system_score_gemma":0.06446832,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000462421,"about_ca_topic_score_gemma":0.0005760095,"domain_scores_codex":[0.9971265,0.00003126776,0.0005296152,0.0008828969,0.0005296607,0.0009000925],"domain_scores_gemma":[0.9978495,0.0003570204,0.0001462015,0.0007549953,0.0004923735,0.0003999595],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.2134644,0.03536331,0.03477977,0.1041548,0.05085934,0.0124273,0.02184926,0.02967917,0.04575286,0.005842297,0.02456727,0.4212603],"study_design_scores_gemma":[0.7166669,0.02294189,0.00280047,0.001623022,0.002625811,0.001061996,0.0001375772,0.05245003,0.1618124,0.0003386718,0.03644025,0.00110094],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9926806,0.002938631,0.0001899616,0.0001181324,0.0001544956,0.00343962,0.0001740647,0.0001062357,0.0001982518],"genre_scores_gemma":[0.9926962,0.000628784,0.002156383,0.00009904639,0.0007241244,0.001150032,0.0006749137,0.0001400641,0.001730467],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5032026,"threshold_uncertainty_score":0.9998876,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01772876279167776,"score_gpt":0.2684535897771648,"score_spread":0.250724826985487,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}